A multinational pharmacoeconomic evaluation of acute major depressive disorder (MDD): a comparison of cost-effectiveness between venlafaxine, SSRIs and TCAs.
about
Selective serotonin reuptake inhibitors (SSRIs) for autism spectrum disorders (ASD)Selective serotonin reuptake inhibitors (SSRIs) for autism spectrum disorders (ASD)The personal and national costs of mental health conditions: impacts on income, taxes, government support payments due to lost labour force participationDesvenlafaxine in major depressive disorder: an evidence-based review of its place in therapy.Methodologies used in cost-effectiveness models for evaluating treatments in major depressive disorder: a systematic reviewDesvenlafaxine in the treatment of major depressive disorder.Assessing the economic impact of psychiatric disorders: where to begin?Vagus nerve stimulation for the treatment of depression and other neuropsychiatric disorders.A Danish cost-effectiveness model of escitalopram in comparison with citalopram and venlafaxine as first-line treatments for major depressive disorder in primary care.Quality assessment of published health economic analyses from South America.Vagus nerve stimulation for epilepsy and depressionComparisons between psychotropic drugs: must the risk of side effects dictate our practices?Cost-effectiveness of combination therapy versus antidepressant therapy for management of depression in Japan.Do productivity costs matter?: the impact of including productivity costs on the incremental costs of interventions targeted at depressive disorders.The prospective, 24-week assessment of cost-efficacy of and compliance to antidepressant medications in a rural setting (PACECAR) study.Cost of depression: current assessment and future directions.Efficacy, effectiveness and efficiency of escitalopram in the treatment of major depressive and anxiety disorders.Cost-effectiveness of adjunctive therapy with atypical antipsychotics for acute treatment of major depressive disorder.The association between labour force participation and being in income poverty amongst those with mental health problems.
P2860
Q24200368-822B6487-1177-4FC5-B529-69499242A511Q24236316-5A0A4C92-64E8-4820-8494-1C278B96733BQ31007848-500F640B-7F8F-43AA-B4C6-3DA5A2256E0AQ33973909-DBABBF13-C456-4257-9966-5576620EF777Q34148218-33839ACB-3B45-401F-A975-4FE7B33946A7Q34234091-7633E308-A52A-4A0E-8306-D9C78B2E5DE7Q34240974-62811582-8545-44CC-9B41-12F2621F5C94Q34594454-5E0F624B-246F-4E79-BF74-E93FAEE57647Q34622235-E43B4202-EBF4-438D-B00F-4B201E71E2E1Q36466893-DC73077E-588B-4312-85AB-24BFF8D0D597Q37047113-8502535D-8BF8-46BC-9CDD-B18076955CD6Q37339072-430CE104-AFE0-4B28-AB47-C74D743B8431Q37480993-7B78B7C4-664B-484E-A872-A15BF23AD931Q37872289-C82FA872-A87E-4646-9D41-3354F3D9E16AQ38615151-CC82A90E-E023-49A0-8A24-42E4A80F6E60Q40684186-72B6DC72-B0B2-4CA0-AA8C-642402A2AE97Q43042829-986FDA71-1F73-4343-84FF-37ECDD73BD54Q45226871-5A24077F-40CF-4731-A03B-355BF15C41CAQ48592699-27E3BCC1-271F-45EA-867E-6070F9E2FB47
P2860
A multinational pharmacoeconomic evaluation of acute major depressive disorder (MDD): a comparison of cost-effectiveness between venlafaxine, SSRIs and TCAs.
description
2001 nî lūn-bûn
@nan
2001年の論文
@ja
2001年学术文章
@wuu
2001年学术文章
@zh
2001年学术文章
@zh-cn
2001年学术文章
@zh-hans
2001年学术文章
@zh-my
2001年学术文章
@zh-sg
2001年學術文章
@yue
2001年學術文章
@zh-hant
name
A multinational pharmacoeconom ...... n venlafaxine, SSRIs and TCAs.
@en
A multinational pharmacoeconom ...... n venlafaxine, SSRIs and TCAs.
@nl
type
label
A multinational pharmacoeconom ...... n venlafaxine, SSRIs and TCAs.
@en
A multinational pharmacoeconom ...... n venlafaxine, SSRIs and TCAs.
@nl
prefLabel
A multinational pharmacoeconom ...... n venlafaxine, SSRIs and TCAs.
@en
A multinational pharmacoeconom ...... n venlafaxine, SSRIs and TCAs.
@nl
P2093
P1433
P1476
A multinational pharmacoeconom ...... n venlafaxine, SSRIs and TCAs.
@en
P2093
P356
10.1046/J.1524-4733.2001.004001016.X
P577
2001-01-01T00:00:00Z